Bruno Gori

TL;DR: In patients harboring EGFR mutations, the administration of EGFR TKIs is followed by a response rate of 70–80%, and a longer progression-free and overall survival than those obtained with standard chemotherapeutic regimens, this review is focused on the evidence for therapeutic strategies in bone and brain metastases due to lung cancer.

TL;DR: Perfusion CT imaging may allow evaluation of lung cancer angiogenesis demonstrating alterations in vascularity following treatment, and Pearson correlation coefficient showed a significant correlation between baseline values of blood flow and blood volume and CT numbers.

TL;DR: This study shows that palonosetron in combination with aprepitant and dexamethasone is effective to prevent chemotherapy-induced nausea and vomiting in patients treated with cisplatin-based HEC.

TL;DR: The results suggest that the safety profiles regarding cutaneous rash, diarrhea, and mucositis after afatinib, erlotinib, or gefitinib treatment become similar after prompt and correct management.

TL;DR: In patients with advanced or metastatic non-small-cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) positive mutations, the use of EGFR tyrosine kinase inhibitor (TKI) showed to improve survival and safety profile, when compare with standard chemotherapy.